Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DCL-101
- Development stage
- Phase 2
- Lead developer
- Dark Canyon Laboratories
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
DCL-101 is an investigational polyethylene glycol (PEG)-3350 based bowel preparation solution developed by Dark Canyon Labs. It is intended for colon cleansing in adult patients undergoing routine colonoscopy. The formulation is designed to be administered in split doses (3 liters or 4 liters) and was evaluated in Phase 2 clinical trials to compare its safety, tolerability, and efficacy against the standard 4-liter GoLYTELY preparation. Like other PEG-based preparations, DCL-101 functions as an osmotic laxative, utilizing the non-absorbable polymer PEG-3350 to retain water in the colon, thereby inducing a liquid stool that clears the bowel for visualization.
Beyond the preview
Go deeper on DCL-101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DCL-101.